- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.06. | Curasight A/S has successfully completed a directed issue of shares of approximately DKK 20 million | 2 | Cision News | ||
| 22.06. | Curasight A/S announces its intention to carry out a directed issue of shares | 1 | Cision News | ||
| 08.06. | Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT in Aggressive Brain Cancer (Glioblastoma) | 357 | PR Newswire | COPENHAGEN, Denmark, June 8, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company") (Spotlight: CURAS) announces encouraging preliminary readout from its Phase 1 clinical trial... ► Artikel lesen | |
| CURASIGHT Aktie jetzt für 0€ handeln | |||||
| 28.05. | CURASIGHT: Interim report Q1 2026 | 2 | Cision News | ||
| 26.04. | CURASIGHT: Major Shareholding Notification - share transfer and ownership restructuring - related party transaction | 2 | Cision News | ||
| 25.03. | Resolutions of the Annual General Meeting 2026 of Curasight A/S | 2 | Cision News | ||
| 10.03. | CURASIGHT: Notice of Annual General Meeting 2026 | 1 | Cision News | ||
| 06.03. | Curasight reduces convertible debt as Fenja Capital converts and enters into a block trade | 1 | Cision News | ||
| 17.02. | Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston | 302 | PR Newswire | COPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ -- Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies... ► Artikel lesen | |
| 09.02. | CURASIGHT: Major Shareholding Notification | 4 | Cision News | ||
| 12.01. | Curasight reports early positive data from brain cancer treatment trial | 3 | Investing.com | ||
| 12.01. | Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas | 500 | PR Newswire | Clear uptake of uTREAT in aggressive brain cancer (glioblastoma)Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and... ► Artikel lesen | |
| 05.01. | Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week | 377 | PR Newswire | COPENHAGEN, Denmark, Jan. 5, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" - (CPH: CURAS) a clinical-stage theranostic company focused on diagnosing and treating certain... ► Artikel lesen | |
| 18.12.25 | Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT in Brain Cancer | 756 | PR Newswire | Phase 1 trial in aggressive brain cancer (Glioblastoma) is the first clinical trial of uTREAT belonging to Curasight's treatment platformNo patient safety issues were reported The dosing... ► Artikel lesen | |
| 08.12.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 08.12.2025 | 934 | Xetra Newsboard | The following instruments on XETRA do have their first trading 08.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 08.12.2025
Aktien
1 KYG4600C1107 Hope Life International... ► Artikel lesen | |
| 26.11.25 | Curasight's uTREAT Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment | 373 | PR Newswire | Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREATSite given green light by European Medicines Agency (EMA) and is now open for patient... ► Artikel lesen | |
| 26.08.25 | Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT in brain cancer patients | 333 | PR Newswire | Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT belonging to Curasight's treatment platform.Initiation of the study marks a key... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 132,92 | +0,01 % | AbbVie setzt mit Apogee-Übernahme neuen Akzent im Wettlauf um Blockbuster-Biologika | AbbVie stärkt mit der geplanten Übernahme von Apogee Therapeutics seine Position im Markt für Immunologie-Biologika und vertieft damit eine ohnehin schon dominante Wettbewerbsstellung. Der Deal zielt... ► Artikel lesen | |
| QIAGEN | 34,980 | +1,57 % | QIAGEN NV - Stabilität als strategischer Anker | ||
| VERA THERAPEUTICS | 41,200 | 0,00 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen | |
| IMMUNOVANT | 38,790 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,440 | +0,13 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| RECURSION PHARMACEUTICALS | 3,815 | +0,39 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| BIONTECH | 85,20 | -0,18 % | Novo Nordisk sucht Volumen, BioNTech sucht Beweise | Pharmaaktien werden derzeit nicht einheitlich bewertet. Der Markt unterscheidet härter zwischen bereits kommerzialisierten Blockbustern, deren Preise unter Druck geraten, und Biotech-Pipelines, die... ► Artikel lesen | |
| TANGO THERAPEUTICS | 29,460 | 0,00 % | Tango Therapeutics Rides a New Precision Oncology Trend in 2026 | ||
| VOR BIOPHARMA | 20,600 | +0,05 % | Vor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| OLEMA PHARMACEUTICALS | 12,640 | 0,00 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ALUMIS | 26,510 | +0,04 % | ALUMIS INC. - 8-K, Current Report | ||
| NURIX THERAPEUTICS | 23,970 | 0,00 % | Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Trade | ||
| PRAXIS PRECISION MEDICINES | 318,37 | -0,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| ERASCA | 18,470 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| IMMUNOME | 23,620 | +0,04 % | TD Cowen bestätigt Kaufempfehlung für Argenx und verweist auf IMNM-Potenzial |
Das Unternehmen CURASIGHT A/S kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +3,28 % bei einem Aktienkurs von 2,830 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CURASIGHT A/S finden Sie auf Wallstreet Online.